Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Erlend Johannessen Egeland

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Clinical Pharmacology and Therapeutics|May 2, 2020
Chronic Inhibition of CYP3A is Temporarily Reduced by Each Hemodialysis Session in Patients With End-Stage Renal DiseaseErlend Johannessen Egeland, Bartlomiej J Witczak, Hasse Khiabani Zaré, et al.
Transplant International : Official Journal of the European Society for Organ Transplantation|September 26, 2018
High tacrolimus clearance - a risk factor for development of interstitial fibrosis and tubular atrophy in the transplanted kidney: a retrospective single-center cohort studyErlend Johannessen Egeland, Anna Varberg Reisaeter, Ida Robertsen, et al.
Transplantation|September 29, 2017
The Authors' ReplyErlend Johannessen Egeland, Elisabet Størset, Ida Robertsen, et al.
Transplantation|April 29, 2017
High Tacrolimus Clearance Is a Risk Factor for Acute Rejection in the Early Phase After Renal TransplantationErlend Johannessen Egeland, Ida Robertsen, Monica Hermann, et al.
Therapeutic Drug Monitoring|January 12, 2019
A Fully Automated Method for the Determination of Serum Belatacept and Its Application in a Pharmacokinetic Investigation in Renal Transplant RecipientsRolf Anton Klaasen, Erlend Johannessen Egeland, Joe Chan, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Clinical Pharmacology and Therapeutics|May 2, 2020
Chronic Inhibition of CYP3A is Temporarily Reduced by Each Hemodialysis Session in Patients With End-Stage Renal DiseaseErlend Johannessen Egeland, Bartlomiej J Witczak, Hasse Khiabani Zaré, et al.
Transplant International : Official Journal of the European Society for Organ Transplantation|September 26, 2018
High tacrolimus clearance - a risk factor for development of interstitial fibrosis and tubular atrophy in the transplanted kidney: a retrospective single-center cohort studyErlend Johannessen Egeland, Anna Varberg Reisaeter, Ida Robertsen, et al.
Transplantation|September 29, 2017
The Authors' ReplyErlend Johannessen Egeland, Elisabet Størset, Ida Robertsen, et al.
Transplantation|April 29, 2017
High Tacrolimus Clearance Is a Risk Factor for Acute Rejection in the Early Phase After Renal TransplantationErlend Johannessen Egeland, Ida Robertsen, Monica Hermann, et al.
Therapeutic Drug Monitoring|January 12, 2019
A Fully Automated Method for the Determination of Serum Belatacept and Its Application in a Pharmacokinetic Investigation in Renal Transplant RecipientsRolf Anton Klaasen, Erlend Johannessen Egeland, Joe Chan, et al.
Pageof 1